Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases

Current Topics in Medicinal Chemistry

Volumn 6, Issue 4, 2006, Pages 289-316

  Sang, Qing Xiang Amy ^a   Jin, Yonghao ^a   Newcomer, Robert G ^a   Monroe, Sara C ^a   Fang, Xuexun ^a   Hurst, Douglas R ^a   Lee, Seakwoo ^a   Cao, Qiang ^a   Schwartz, Martin A ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

Author keywords

Epigallocatechin gallate; Flavonoids; Long chain fatty acids; MMP 14 overexpression; Stroke; Tumorigenesis

Indexed keywords

CAFFEIC ACID; CGS 27023A; CHLOROGENIC ACID; COLLAGENASE; DIAZEPINE DERIVATIVE; DOXYCYCLINE HYCLATE; ELAIDIC ACID; EPIGALLOCATECHIN GALLATE; FLAVONOID; GELATINASE A; GELATINASE B; HONOKIOL; HYDROXAMIC ACID DERIVATIVE; INTERSTITIAL COLLAGENASE; LONG CHAIN FATTY ACID; MAGNOLOL; MATRILYSIN; MATRILYSIN INHIBITOR; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; OLEIC ACID; PARINARIC ACID; POLYPHENOL; PRINOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNINDEXED DRUG;

BRAIN PROTECTION; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE TARGETING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR WEIGHT; NONHUMAN; PERIODONTAL DISEASE; PROTEIN EXPRESSION; REVIEW; STROKE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASMS; PROTEASE INHIBITORS;

EID: 33646136687     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606776287045     Document Type: Review

References (236)

1. Sternlicht, M. D.; Bergers, G. Matrix Metalloproteinases as Emerging Targets in Anticancer Therapy: Status and Prospects. Emerging Opin. Therap. Targets 2000, 4, 609-633.
2. Sternlicht, M. D.; Werb, Z. How Matrix Metalloproteinases Regulate Cell Behavior. Annu. Rev. Cell Dev. Biol 2001, 17, 463-516.
3. D'Armiento, J.; DiColandrea, T.; Dalal, S. S.; Okada, Y.; Huang, M. T.; Conney, A. H.; Chada, K. Collagenase Expression in Transgenic Mouse Skin Causes Hyperkeratosis and Acanthosis and Increases Susceptibility to Tumorigenesis. Mol. Cell Biol. 1995, 15, 5732-5739.
4. Ha, H. Y.; Moon, H. B.; Nam, M. S.; Lee, J. W.; Ryoo, Z. Y.; Lee, T.H.; Lee, K. K.; So, B. J.; Sato, H.; Seiki, M.; Yu, D. Y. Overexpression of Membrane-Type Matrix Metalloproteinase-1 Gene Induces Mammary Gland Abnormalities and Adenocarcinoma in Transgenic Mice. Cancer Res. 2001, 61, 984-990.
5. Rudolph-Owen, L. A.; Chan, R.; Muller, W. J.; Matrisian, L. M. The Matrix Metalloproteinase Matrilysin Influences Early-Stage Mammary Tumorigenesis. Cancer Res. 1998, 58, 5500-5506.
6. Sternlicht, M. D.; Lochter, A.; Sympson, C. J.; Huey, B.; Rougier, J. P.; Gray, J. W.; Pinkel, D.; Bissell, M. J.; Werb, Z. The Stromal Proteinase MMP-3/Stromelysin-1 Promotes Mammary Carcinogenesis. Cell 1999, 98, 137-146.
7. Sympson, C. J.; Bissell, M. J.; Werb, Z. Mammary Gland Tumor Formation in Transgenic Mice Overexpressing Stromelysin-1. Semin. Cancer Biol. 1995, 6, 159-163.
8. Colandrea, T. D.; D'Armiento, J.; Kesari, K. V.; Chada, K. K. Collagenase Induction Promotes Mouse Tumorigenesis by Two Independent Pathways. Mol. Carcinog. 2000, 29, 8-16.
9. Bergers, G.; Brekken, R.; McMahon, G.; Vu, T. H.; Itoh, T.; Tamaki, K.; Tanzawa, K.; Thorpe, P.; Itohara, S.; Werb, Z.; Hanahan, D. Matrix Metalloproteinase-9 Triggers the Angiogenic Switch During Carcinogenesis. Nat. Cell Biol. 2000, 2, 737-744.
10. Coussens, L. M.; Tinkle, C. L.; Hanahan, D.; Werb, Z. MMP-9 Supplied by Bone Marrow-Derived Cells Contributes to Skin Carcinogenesis. Cell 2000, 10, 491-490.
11. Itoh, T.; Tanioka, M.; Yoshida, H.; Yoshioka, T.; Nishimoto, H.; Itohara, S. Reduced Angiogenesis and Tumor Progression in Gelatinase A-Deficient Mice. Cancer Res. 1998, 58, 1048-1051.
12. Masson, R.; Lefebvre, O.; Noel, A.; Fahime, M. E.; Chenard, M. P.; Wendling, C.; Kebers, F.; LeMeur, M.; Dierich, A.; Foidart, J. M.; Basset, P.; Rio, M. C. In vivo Evidence That the Stromelysin-3 Metalloproteinase Contributes in a Paracrine Manner to Epithelial Cell Malignancy. J. Cell Biol. 1998, 140, 1535-1541.
13. Wilson, C. L.; Heppner, K. J.; Labosky, P. A.; Hogan, B. L.; Matrisian, L. M. Intestinal Tumorigenesis Is Suppressed in Mice Lacking the Metalloproteinase Matrilysin. Proc. Natl. Acad. Sci. USA 1997, 94, 1402-1407
14. Belien, A. T.; Paganetti, P. A.; Schwab, M. E. Membrane-Type 1 Matrix Metalloprotease (MT1-MMP) Enables Invasive Migration of Glioma Cells in Central Nervous System White Matter. J. Cell Biol. 1999, 144, 373-384.
15. Chun, T. H.; Sabeh, F.; Ota, I.; Murphy, H.; McDonagh, K. T.; Holmbeck, K.; Birkedal-Hansen, H.; Allen, E. D.; Weiss, S. J. MT1-MMP-Dependent Neovessel Formation within the Confines of the Three-Dimensional Extracellular Matrix. J. Cell Biol. 2004, 167, 757-767.
16. Hotary, K.; Allen, E.; Punturieri, A.; Yana, I.; Weiss, S. J. Regulation of Cell Invasion and Morphogenesis in a Three-Dimensional Type I Collagen Matrix by Membrane-Type Matrix Metalloprotemases 1, 2, and 3. J. Cell Biol. 2000, 149, 1309-1323.
17. Hotary, K. B.; Yana, I.; Sabeh, F.; Li, X. Y.; Holmbeck, K.; Birkedal-Hansen, H.; Allen, E. D.; Hiraoka, N.; Weiss, S. J. Matrix Metalloproteinases (MMPs) Regulate Fibrin-Invasive Activity Via MT1-MMP-Dependent and -Independent Processes. J. Exp. Med. 2002, 195, 295-308.
18. Kondraganti, S.; Mohanam, S.; Chintala, S. K.; Kin, Y.; Jasti, S. L.; Nirmala, C.; Lakka, S. S.; Adachi, Y.; Kyritsis, A. P.; Ali-Osman, F.; Sawaya, R.; Fuller, G. N.; Rao, J. S. Selective Suppression of Matrix Metalloproteinase-9 in Human Glioblastoma Cells by Antisense Gene Transfer Impairs Glioblastoma, Cell Invasion. Cancer Res. 2000, 60, 6851-6855.
19. Lakka, S. S.; Rajan, M.; Gondi, C.; Yanamandra, N.; Chandrasekar, N.; Jasti, S. L.; Adachi, Y.; Siddique, K.; Gujrati, M.; Olivero, W.; Dinh, D. H.; Kouraklis, G.; Kyritsis, A. P.; Rao, J. S. Adenovirus-Mediated Expression of Antisense MMP-9 in Glioma Cells Inhibits Tumor Growth and Invasion. Oncogene 2002, 21, 8011-8019.
20. Lochter, A.; Galosy, S.; Muschler, J.; Freedman, N.; Werb, Z.; Bissell, M. J. Matrix Metalloproteinase Stromelysin-1 Triggers a Cascade of Molecular Alterations That Leads to Stable Epithelial-to-Mesenchymal Conversion and a Premalignant Phenotype in Mammary Epithelial Cells. J. Cell Biol. 1997, 139, 1861-1872.
21. Sabeh, F.; Ota, I.; Holmbeck, K.; Birkedal-Hansen, H.; Soloway, P.; Balbin, M.; Lopez-Otin, C.; Shapiro, S.; Inada, M.; Krane, S.; Allen, E.; Chung, D.; Weiss, S. J. Tumor Cell Traffic through the Extracellular Matrix Is Controlled by the Membrane-Anchored Collagenase MT1-MMP. J. Cell Biol. 2004, 167, 769-781.
22. Sanceau, J.; Truchet, S.; Bauvois, B. Matrix Metalloproteinase-9 Silencing by RNA Interference Triggers the Migratory-Adhesive Switch in Ewing's Sarcoma Cells. J. Biol. Chem. 2003, 278, 36537-36546.
23. Ueda, J.; Kajita, M.; Suenaga, N.; Fujii, K.; Seiki, M. Sequence-Specific Silencing of MT1-MMP Expression Suppresses Tumor Cell Migration and Invasion: Importance of MT1-MMP as a Therapeutic Target for Invasive Tumors. Oncogene 2003, 22, 8716-8722.
24. Kim, J.; Yu, W.; Kovalski, K.; Ossowski, L. Requirement for Specific Proteases in Cancer Cell Intravasation as Revealed by a Novel Semiquantitative PCR-Based Assay. Cell 1998, 94, 353-362.
25. Fang, J.; Shing, Y.; Wiederschain, D.; Yan, L.; Butterfield, C.; Jackson, G.; Harper, J.; Tamvakopoulos, G.; Moses, M. A. Matrix Metalloproteinase-2 Is Required for the Switch to the Angiogenic Phenotype in a Tumor Model. Proc. Natl. Acad. Sci, USA 2000, 97, 3884-3889.
26. Hiratsuka, S.; Nakamura, K.; Iwai, S.; Murakami, M.; Itoh, T.; Kijima, H.; Shipley, J. M.; Senior, R. M.; Shibuya, M. MMP-9 Induction by Vascular Endothelial Growth Factor Receptor-1 Is Involved in Lung-Specific Metastasis. Cancer Cell 2002, 2, 289-300.
27. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix Metalloproteinase Inhibitors and Cancer: Trials and Tribulations. Science 2002, 295, 2387-2392.
28. Gatto, C.; Rieppi, M.; Borsotti, P.; Innocenti, S.; Ceruti, R.; Drudis, T.; Scanziani, E.; Casazza, A. M.; Taraboletti, G.; Giavazzi, R. BAY 12-9566, a Novel Inhibitor of Matrix Metalloproteinases with Antiangiogenic Activity. Clin. Cancer Res. 1999, 5, 3603-3607.
29. Lein, M.; Jung, K.; Ortel, B.; Stephan, C.; Rothaug, W.; Juchem, R.; Johannsen, M.; Deger, S.; Schnorr, D.; Loening, S.; Krell, H. W. The New Synthetic Matrix Metalloproteinase Inhibitor (Roche 28-2653) Reduces Tumor Growth and Prolongs Survival in a Prostate Cancer Standard Rat Model. Oncogene 2002, 21, 2089-2096.
30. Nemeth, J. A.; Yousif, R.; Herzog, M.; Che, M.; Upadhyay, J.; Shekarriz, B.; Bhagat, S.; Mullins, C.; Fridman, R.; Cher, M. L. Matrix Metalloproteinase Activity, Bone Matrix Turnover, and Tumor Cell Proliferation in Prostate Cancer Bone Metastasis. J. Natl. Cancer Inst. 2002, 94, 17-25.
31. Hotary, K. B.; Allen, E. D.; Brooks, P. C.; Datta, N. S.; Long, M. W.; Weiss, S. J. Membrane Type I Matrix Metalloproteinase Usurps Tumor Growth Control Imposed by the Three-Dimensional Extracellular Matrix. Cell 2003, 114, 3345.
32. Koshikawa, N.; Giannelli, G.; Cirulli, V.; Miyazaki, K.; Quaranta, V. Role of Cell Surface Metalloprotease MT1-MMP in Epithelial Cell Migration over Laminin-5. J. Cell Biol. 2000, 148, 615-624.
33. Endo, K.; Takino, T.; Miyamori, H.; Kinsen, H.; Yoshizaki, T.; Furukawa, M.; Sato, H. Cleavage of Syndecan-1 by Membrane Type Matrix Metalloproteinase-1 Stimulates Cell Migration. J. Biol. Chem. 2003, 278, 40764-40770.
34. Kajita, M.; Itoh, Y.; Chiba, T.; Mori, H.; Okada, A.; Kinoh, H.; Seiki, M. Membrane-Type 1 Matrix Metalloproteinase Cleaves CD44 and Promotes Cell Migration. J. Cell Biol. 2001, 153, 893-904.
35. Ochieng, J.; Fridman, R.; Nangia-Makker, P.; Kleiner, D. E.; Liotta, L. A.; Stetler-Stevenson, W. G.; Raz, A. Galectin-3 Is a Novel Substrate for Human Matrix Metalloproteinases-2 and -9. Biochemistry 1994, 33, 14109-14114.
36. Noe, V.; Fingleton, B.; Jacobs, K.; Crawford, H. C.; Vermeulen, S.; Steelant, W.; Bruyneel, E.; Matrisian, L. M.; Marcel, M. Release of an Invasion Promoter E-Cadherin Fragment by Matrilysin and Stromelysin-1. J. Cell Sci. 2001, 114, 111-118.
37. Giannelli, G.; Falk-Marzillier, J.; Schiraldi, O.; Stetler-Stevenson, W. G.; Quaranta, V. Induction of Cell Migration by Matrix Metalloprotease-2 Cleavage of Laminin-5. Science 1997, 277, 225-228.
38. Xu, J.; Rodriguez, D.; Petitclerc, E.; Kim, J. J.; Hangai, M.; Moon, Y. S.; Davis, G. E.; Brooks, P. C. Proteolytic Exposure of a Cryptic Site within Collagen Type IV Is Required for Angiogenesis and Tumor Growth in vivo. J. Cell Blol. 2001, 154, 1069-1079.
39. Imai, K.; Hiramatsu, A.; Fukushima, D.; Pierschbacher, M. D.; Okada, Y. Degradation of Decorin by Matrix Metalloproteinases: Identification of the Cleavage Sites, Kinetic Analyses and Transforming Growth Factor-Betal Release. Biochem. J. 1997, 322, 809-814.
40. Gearing, A. J.; Beckett, P.; Christodoulou, M.; Churchill, M.; Clements, J.; Davidson, A. H.; Drummond, A. H.; Galloway, W. A.; Gilbert, R.; Gordon, J. L.; Leber, T. M.; Mangan, M.; Miller, K.; Nayee, P.; Owen, K.; Patel, S.; Thomas, W.; Wells, G.; Wood, L. M.; Woolley, K. Processing of Tumour Necrosis Factor-Alpha Precursor by Metalloproteinases. Nature 1994, 370, 555-557.
41. Karsdal, M. A.; Larsen, L.; Engsig, M. T.; Lou, H.; Ferreras, M.; Lochter, A.; Delaisse, J. M.; Foged, N. T. Matrix Metalloproteinase-Dependent Activation of Latent Transforming Growth Factor-Beta Controls the Conversion of Osteoblasts into Osteocytes by Blocking Osteoblast Apoptosis. J. Biol. Chem. 2002, 277, 44061-44067.
42. Mu, D.; Cambier, S.; Fjellbirkeland, L.; Baron, J. L.; Munger, J. S.; Kawakatsu, H.; Sheppard, D.; Broaddus, V. C.; Nishimura, S. L. The Integrin Alpha(V)Beta8 Mediates Epithelial Homeostasis through MT1-MMP-Dependent Activation of TGF-Betal. J. Cell Biol. 2002, 157, 493-507.
43. Yu, Q.; Stamenkovic, I. Cell Surface-Localized Matrix Metalloproteinase-9 Proteolytically Activates TGF-Beta and Promotes Tumor Invasion and Angiogenesis. Genes Dev. 2000, 14, 163-176.
44. Fowlkes, J. L.; Enghild, J. J.; Suzuki, K.; Nagase, H. Matrix Metalloproteinases Degrade Insulin-Like Growth Factor-Binding Protein-3 in Dermal Fibroblast Cultures. J. Biol. Chem. 1994. 269, 25742-25746.
45. Mitsiades, N.; Yu, W. H.; Poulaki, V.; Tsokos, M.; Stamenkovic, I. Matrix Metalloproteinase-7-Mediated Cleavage of Fas Ligand Protects Tumor Cells from Chemotherapeutic Drug Cytotoxicity. Cancer Res. 2001, 61, 577-581.
46. Strand, S.; Vollmer, P.; van den Abeelen, L.; Gottfried, D.; Alla, V.; Heid, H.; Kuball, J.; Theobald, M.; Galle, P. R.; Strand, D. Cleavage of CD95 by Matrix Metalloproteinase-7 Induces Apoptosis Resistance in Tumour Cells. Oncogene 2004, 23, 3732-3736.
47. Sounni, N. E.; Devy, L.; Hajitou, A.; Frankenne, F.; Munaut, C.; Gilles, C.; Deroanne, C.; Thompson, E. W.; Foidart, J. M.; Noel, A. MT1-MMP Expression Promotes Tumor Growth and Angiogenesis through an up-Regulation of Vascular Endothelial Growth Factor Expression. FASEB J. 2002, 16, 555-564.
48. Sounni, N. E.; Roghi, C.; Chabottaux, V.; Janssen, M.; Munaut, C.; Maquoi, E.; Galvez, B. G.; Gilles, C.; Frankenne, F.; Murphy, G.; Foidart, J. M.; Noel, A. Up-Regulation of Vascular Endothelial Growth Factor-A by Active Membrane-Type 1 Matrix Metalloproteinase through Activation of Src-Tyrosine Kinases. J. Biol. Chem. 2004, 279, 13564-13574.
49. Balbin, M.; Fueyo, A.; Tester, A. M.; Pendas, A. M.; Pitiot, A. S.; Astudillo, A.; Overall, C. M.; Shapiro, S. D.; Lopez-Otin, C. Loss of Collagenase-2 Confers Increased Skin Tumor Susceptibility to Male Mice. Nat Genet. 2003, 35, 252-257.
50. Hamano, Y.; Zeisberg, M.; Sugimoto, H.; Lively, J. C.; Maeshima, Y.; Yang, C.; Hynes, R. O.; Werb, Z.; Sudhakar, A.; Kalluri, R. Physiological Levels of Tumstatin, a Fragment of Collagen IV Alpha3 Chain, Are Generated by MMP-9 Proteolysis and Suppress Angiogenesis Via Alphav Beta3 Integrin. Cancer Cell 2003, 3, 589-601.
51. Dong, Z.; Kumar, R.; Yang, X.; Fidler, I. J. Macrophage-Derived Metalloelastase Is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma. Cell 1997, 88, 801-810.
52. O'Reilly, M. S.; Wiederschain, D.; Stetler-Stevenson, W. G.; Folkman, J.; Moses, M. A. Regulation of Angiostatin Production by Matrix Metalloproteinase-2 in a Model of Concomitant Resistance. J. Biol. Chem. 1999, 274, 29568-29571.
53. Patterson, B. C.; Sang, Q. A. Angiostatin-Converting Enzyme Activities of Human Matrilysin (MMP-7) and Gelatinase B/Type IV Collagenase (MMP-9). J. Biol. Chem. 1997, 272, 28823-28825.
54. Pozzi, A.; Moberg, P. E.; Miles, L. A.; Wagner, S.; Soloway, P.; Gardner, H. A. Elevated Matrix Metalloprotease and Angiostatin Levels in Integrin Alpha 1 Knockout Mice Cause Reduced Tumor Vascularization. Proc. Natl. Acad. Sci. USA 2000, 97, 2202-2207.
55. Chen, X.; Su, Y.; Fingleton, B.; Acuff, H.; Matrisian, L. M.; Zent, R.; Pozzi, A. An Orthotopic Model of Lung Cancer to Analyze Primary and Metastatic NSCLC Growth in Integrin Alphal-Null Mice. Clin. Exp. Metastasis 2005, 22, 185-193.
56. Sierevogel, M. J.; Pasterkamp, G.; De Kleijn, D. P.; Strauss, B. H. Matrix Metalloproteinases: A Therapeutic Target in Cardiovascular Disease. Curr. Pharm. Des. 2003, 9, 1033-1040.
57. Cunningham, L. A.; Wetzel, M.; Rosenberg, G. A. Multiple Roles for MMPs and TIMPs in Cerebral Ischemia. Glia. 2005, 50, 329-339.
58. Chen, J.; Tung, C. H.; Allport, J. R.; Chen, S.; Weissleder, R.; Huang, P. L. Near-Infrared Fluorescent Imaging of Matrix Metalloproteinase Activity after Myocardial Infarction. Circulation 2005, 111, 1800-1805.
59. Wu, T. C.; Len, H. B.; Lin, W. T.; Lin, C. P.; Lin, S. J.; Chen, J. W. Plasma Matrix Metalloproteinase-3 Level Is an Independent Prognostic Factor in Stable Coronary Artery Disease. Eur. J. Clin. Invest 2005, 35, 537-545.
60. Vine, N.; Powell, J. T. Metalloproteinases in Degenerative Aortic Disease. Clin. Sci. 1991, 81, 233-239.
61. Creemers, E. E.; Cleutjens, J. P.; Smits, J. F.; Daemen, M. J. Matrix Metalloproteinase Inhibition after Myocardial Infarction: A New Approach to Prevent Heart Failure? Circ. Res. 2001, 89, 201-210.
62. Villarreal, F. J.; Griffin, M.; Omens, J.; Dillmann, W.; Nguyen, J.; Covell, J. Early Short-Term Treatment with Doxycycline Modulates Postinfarction Left Ventricular Remodeling. Circulation 2003, 108, 1487-1492.
63. Griffin, M. O.; Jinno, M.; Miles, L. A.; Villarreal, F. J. Reduction of Myocardial Infarct Size by Doxycycline: A Role for Plasmin Inhibition. Mol. Cell Biochem. 2005, 270, 1-11.
64. Newby, A. C. Dual Role of Matrix Metalloproteinases (Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture. Physiol. Rev. 2005, 85, 1-31.
65. Molloy, K. J.; Thompson, M. M.; Jones, J. L.; Schwalbe, E. C.; Bell, P. R.; Naylor, A. R.; Loftus, I. M. Unstable Carotid Plaques Exhibit Raised Matrix Metalloproteinase-8 Activity. Circulation 2004, 110, 337-343.
66. Furman, C.; Copin, C.; Kandoussi, M.; Davidson, R.; Moreau, M.; McTaggiart, F.; Chapman, M. J.; Fruchart, J. C.; Rouis, M. Rosuvastatin Reduces MMP-7 Secretion by Human Monocyte-Derived Macrophages: Potential Relevance to Atherosclerotic Plaque Stability. Atherosclerosis 2004, 174, 93-98.
67. van Oostrom, O.; Velema, E.; Schoneveld, A. H.; de Vries, J. P.; de Bruin, P.; Seldenrijk, C. A.; de Kleijn, D. P.; Busser, E.; Moll, F. L.; Verheijen, J. H.; Virmani, R.; Pasterkamp, G. Age-Related Changes in Plaque Composition: A Study in Patients Suffering from Carotid Artery Stenosis. Cardiovasc. Pathol. 2005, 14, 126-134.
68. Ray, B. K.; Shakya, A.; Turk, J. R.; Apte, S. S.; Ray, A. Induction of the MMP-14 Gene in Macrophages of the Atherosclerotic Plaque: Role of SAF-1 in the Induction Process. Circ. Res. 2004, 95, 1082-1090.
69. Kuzuya, M.; Kanda, S.; Sasaki, T.; Tamaya-Mori, N.; Cheng, X. W.; Itoh, T.; Itobara, S.; Iguchi, A. Deficiency of Gelatinase A Suppresses Smooth Muscle Cell Invasion and Development of Experimental Intimal Hyperplasia. Circulation 2003, 108, 1375-1381.
70. Kato, R.; Momiyama, Y.; Ohmori, R.; Taniguchi, H.; Nakamura, H.; Ohsuzu, F. Levels of Matrix Metalloproteinase-1 in Patients with and without Coronary Artery Disease and Relation to Complex and Noncomplex Coronary Plaques. Am. J. Cardiol. 2005, 95, 90-92.
71. Masuda, T.; Nakayama, Y. Development of a Water-Soluble Matrix Metalloproteinase Inhibitor as an Intra-Arterial Infusion Drug for Prevention of Restenosis after Angioplasty. J. Med. Chem. 2003, 46, 3497-3501.
72. Caldwell, R. A.; Vyavahare, N.; Langan, E. M., 3rd, LaBerge, M. Society of Biomaterials Graduate Degree Candidate Student Research Award. Matrix Metalloproteinase Inhibitor within an Absorbable Coating for Vascular Applications: Delivery Device Characterization and Reduction of Smooth Muscle Cell Proliferation and Migration. J. Biomed. Mater. Res. A. 2003, 67, 1-10.
73. Li, C.; Cantor, W. J.; Nili, N.; Robinson, R.; Fenkell, L.; Tran, Y. L.; Whittingham, H. A.; Tsui, W.; Cheema, A. N.; Sparkes, J. D.; Pritzker, K.; Levy, D. E.; Strauss, B. H. Arterial Repair after Stenting and the Effects of GM6001, a Matrix Metalloproteinase Inhibitor. J. Am. Coll. Cardiol. 2002, 39, 1852-1858.
74. van Beusekom, H. M.; Post, M. J.; Whelan, D. M.; de Smet, B. J.; Duncker, D. J.; van der Giessen, W. J. Metalloproteinase Inhibition by Batimastat Does Not Reduce Neointimal Thickening in Stented Atherosclerotic Porcine Femoral Arteries. Cardiovasc. Radiat. Med. 2003, 4, 186-191.
75. Cherr, G. S.; Motew, S. J.; Travis, J. A.; Fingerle, J.; Fisher, L.; Brandl, M.; Williams, J. K.; Geary, R. L. Metalloproteinase Inhibition and the Response to Angioplasty and Stenting in Atherosclerotic Primates. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 161-166
76. Matsusaka, H.; Ikeuchi, M.; Matsushima, S.; Ide, T.; Kubota, T.; Feldman, A. M.; Takeshita, A.; Sunagawa, K.; Tsutsui, H.; Ikeda, U.; Shimada, K. Selective Disruption of Matrix Metalloproteinase-2 Gene Exacerbates Myocardial Inflammation and Dysfunction in Mice with Cytokine-Induced Cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2005, 289, H1858-H1864. Epub 2005 Jun 3.
77. Ikeda, U.; Shimada, K. Matrix Metalloproteinases and Coronary Artery Diseases. Clin. Cardiol. 2003, 26, 55-59.
78. Rosell, A.; Alvarez-Sabin, J.; Arenillas, J. F.; Rovira, A.; Delgado, P.; Fernandez-Cadenas, I.; Penalba, A.; Molina, C. A.; Montaner, J. A Matrix Metalloproteinase Protein Array Reveals a Strong Relation between MMP-9 and MMP-13 with Diffusion-Weighted Image Lesion Increase in Human Stroke. Stroke 2005, 36, 1415-1420.
79. Gu, Z.; Cui, J.; Brown, S.; Fridman, R.; Mobashery, S.; Strongin, A. Y.; Lipton, S. A. A Highly Specific Inhibitor of Matrix Metalloproteinase-9 Rescues Laminin from Proteolysis and Neurons from Apoptosis in Transient Focal Cerebral Ischemia. J. Neurosci. 2005, 25, 6401-6408.
80. Gursoy-Ozdemir, Y.; Qiu, J.; Matsuoka, N.; Bolay, H.; Bermpohl, D.; Jin, H.; Wang, X.; Rosenberg, G. A.; Lo, E. H.; Moskowitz, M. A. Cortical Spreading Depression Activates and Upregulates MMP-9. J. Clin. Invest. 2004, 113, 1447-1455.
81. Pfefferkorn, T.; Rosenberg, G. A. Closure of the Blood-Brain Barrier by Matrix Metalloproteinase Inhibition Reduces rtPA-Mediated Mortality in Cerebral Ischemia with Delayed Reperfusion. Stroke 2003, 34, 2025-2030.
82. Koistinaho, M.; Malm, T. M.; Kettunen, M. I.; Goldsteins, G.; Starckx, S.; Kauppinen, R. A.; Opdenakker, G.; Koistinaho, J. Minocycline Protects against Permanent Cerebral Ischemia in Wild Type but Not in Matrix Metalloprotease-9-Deficient Mice. J. Cereb. Blood Flow Metab. 2005, 25, 460-467.
83. Gidday, J. M.; Gasche, Y. G.; Copin, J. C.; Shah, A. R.; Perez, R. S.; Shapiro, S. D.; Chan, P. H.; Park, T. S. Leukocyte-Derived Matrix Metalloproteinase-9 Mediates Blood-Brain Barrier Breakdown and Is Proinflammatory after Transient Focal Cerebral Ischemia. Am. J. Physiol. Heart Circ. Physiol. 2005, 289, H558-568.
84. Brew, K.; Dinakarpandian, D.; Nagase, H. Tissue Inhibitors of Metalloproteinases: Evolution, Structure and Function. Biochim. Biophys. Acta 2000, 1477, 267-283.
85. Nagase, H.; Brew, K. Designing TIMP (Tissue Inhibitor of Metalloproteinases) Variants That Are Selective Metalloproteinase Inhibitors. Biochem. Soc. Symp. 2003, 201-212.
86. Lambert, E.; Dasse, E.; Haye, B.; Petitfrere, E. TIMPs as Multifacial Proteins. Crit. Rev. Oncol. Hematol. 2004, 49, 187-198.
87. Berton, A.; Rigot, V.; Huet, E.; Decarme, M.; Eeckhout, Y.; Patthy, L.; Godeau, G.; Hornebeck, W.; Bellon, G.; Emonard, H. Involvement of Fibronectin Type II Repeats in the Efficient Inhibition of Gelatinases A and B by Long-Chain Unsaturated Fatty Acids. J. Biol. Chem. 2001, 276, 20458-20465.
88. Curtis, C. L.; Hughes, C. E.; Flannery, C. R.; Little, C. B.; Harwood, J. L.; Caterson, B. N-3 Fatty Acids Specifically Modulate Catabolic Factors Involved in Articular Cartilage Degradation. J. Biol. Chem. 2000, 275, 721-724.
89. Emonard, H.; Marcq, V.; Mirand, C.; Hornebeck, W. Inhibition of Gelatinase A by Oleic Acid. Ann. N. Y. Acad. Sci. 1999, 878, 647-649.
90. Polette, M.; Huet, E.; Birembaut, P.; Maquart, F. X.; Hornebeck, W.; Emonard, H. Influence of Oleic Acid on the Expression, Activation and Activity of Gelatinase A Produced by Oncogene-Transformed Human Bronchial Epithelial Cells. Int. J. Cancer 1999, 80, 751-755.
91. Suzuki, I.; Iigo, M.; Ishikawa, C.; Kuhara, T.; Asamoto, M.; Kunimoto, T.; Moore, M. A.; Yazawa, K.; Araki, E.; Tsuda, H. Inhibitory Effects of Oleic and Docosahexaenoic Acids on Lung Metastasis by Colon-Carcinoma-26 Cells Are Associated with Reduced Matrix Metalloproteinase-2 and -9 Activities. Int. J. Cancer 1997, 73, 607-612.
92. Ashe, B. M.; Zimmerman, M. Specific Inhibition Granulocyte Elastase by Cis-Unsaturated Fatty Acids and Activation by the Corresponding Alcohols. Biochem. Biophys. Res. Commun. 1977, 75, 194-199.
93. Tyagi, S. C.; Simon, S. R. Parinaric Acids as Probes of Binding Domains in Neutrophil Elastase. J. Biol. Chem. 1991, 266, 15185-15191.
94. Higazi, A. A.; Aziza, R.; Samara, A. A.; Mayer, M. Regulation of Fibrinolysis by Non-Esterified Fatty Acids. Biochem. J. 1994, 300, 251-255.
95. Higazi, A. A.; Finci-Yeheskel, Z.; Samara, A. A.; Aziza, R.; Mayer, M. Stimulation of Plasmin Activity by Oleic Acid. Biochem. J. 1992, 282, 863-866.
96. Fujita, M.; Nakao, Y.; Matsunaga, S.; van Soest, R. W.; Itoh, Y.; Seiki, M.; Fusetani, N. Callysponginol Sulfate A, an MT1-MMP Inhibitor Isolated from the Marine Sponge Callyspongia Truncata. J. Nat. Prod. 2003, 66, 569-571.
97. Annabi, B.; Lachambre, M. P.; Bousquet-Gagnon, N.; Page, M.; Gingras, D.; Beliveau, R. Green Tea Polyphenol (-)- Epigallocatechin 3-Gallate Inhibits MMP-2 Secretion and MT1-MMP-Driven Migration in Glioblastoma Cells. Biochim. Biophys Acta. 2002, 1542, 209-220.
98. Demeule, M.; Brossard, M.; Page, K.; Gingras, D.; Beliveau, R. Matrix Metalloproteinase Inhibition by Green Tea Catechins. Biochim. Biophys. Acta 2000, 1478, 51-60.
99. Yamakawa, S.; Asai, T.; Uchida, T.; Matsukawa, M.; Akizawa, T.; Oku, N. (-)-Epigallocatechin Gallate Inhibits Membrane-Type 1 Matrix Metalloproteinase, MT1-MMP, and Tumor Angiogenesis. Cancer Lett. 2004, 210, 47-55.
100. Yang, J.; Wei, D.; Liu, J. Repressions of MMP-9 Expression and NF-Kappa B Localization Are Involved in Inhibition of Lung Carcinoma 95-D Cell Invasion by (-)-Epigallocatechin-3-Gallate. Biomed. Pharmacother. 2005, 59, 98-103.
101. Vayalil, P. K.; Katiyar, S. K. Treatment of Epigallocatechin-3-Gallate Inhibits Matrix Metalloproteinases-2 and -9 Via Inhibition of Activation of Mitogen-Activated Protein Kinases, C-Jun and NF-Kappa B in Human Prostate Carcinoma DU-145 Cells. Prostate 2004, 59, 33-42.
102. Cheng, X. W.; Kuzuya, M.; Kanda, S.; Maeda, K.; Sasaki, T.; Wang, Q. L.; Tamaya-Mori, N.; Shibata, T.; Iguchi, A. Epigallocatechin-3-Gallate Binding to MMP-2 Inhibits Gelatinolytic Activity without Influencing the Attachment to Extracellular Matrix Proteins but Enhances MMP-2 Binding to TIMP-2. Arch. Biochem. Biophys. 2003, 415, 126-132.
103. Ahmed, S.; Wang, N.; Lalonde, M.; Goldberg, V. M.; Haqqi, T. M. Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) Differentially Inhibits Interleukin-1 Beta-Induced Expression of Matrix Metalloproteinase-1 and -13 in Human Chondrocytes. J. Pharmacol. Exp. Ther. 2004, 308, 767-773.
104. Song, X. Z.; Xia, J. P.; Bi, Z. G. Effects of (-)-Epigallocatechin-3-Gallate on Expression of Matrix Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-1 in Fibroblasts Irradiated with Ultraviolet A. Chin. Med. J. 2004, 117, 1838-1841.
105. Azam, S.; Hadi, N.; Khan, N. U.; Hadi, S. M. Prooxidant Property of Green Tea Polyphenols Epicatechin and Epigallocatechin-3-Gallate: Implications for Anticancer Properties. Toxicol. In Vitro 2004, 18, 555-561.
106. Umeda, D.; Tachibana, H.; Yamada, K. Epigallocatechin-3-O-Gallate Disrupts Stress Fibers and the Contractile Ring by Reducing Myosin Regulatory Light Chain Phosphorylation Mediated through the Target Molecule 67 kDa Laminin Receptor. Biochem. Biophys. Res. Commun. 2005, 333, 628-635.
107. Adhami, V. M.; Ahmad, N.; Mukhtar, H. Molecular Targets for Green Tea in Prostate Cancer Prevention. J. Nutr. 2003, 133, 2417S-2424S.
108. Huh, S. W.; Bae, S. M.; Kim, Y. W.; Lee, J. M.; Namkoong, S. E.; Lee, I. P.; Kim, S. H.; Kim, C. K. A. W. S. Anticancer Effects of (-)-Epigallocatechin-3-Gallate on Ovarian Carcinoma Cell Lines. Gynecol. Oncol. 2004, 94, 760-768.
109. Yokoyama, M.; Noguchi, M.; Nakao, Y.; Pater, A.; Iwasaka, T. The Tea Polyphenol, (-)-Epigallocatechin Gallate Effects on Growth, Apoptosis, and Telomerase Activity in Cervical Cell Lines. Gynecol. Oncol. 2004, 92, 197-204.
110. Nihal, M.; Ahmad, N.; Mukhtar, H.; Wood, G. S. Anti-Proliferative and Proapoptotic Effects of (-)-Epigallocatechin-3-Gallate on Human Melanoma: Possible Implications for the Chemoprevention of Melanoma. Int. J. Cancer 2005, 114, 513-521.
111. Li, R.; Huang, Y. G.; Fang, D.; Le, W. D. (-)-Epigallocatechin Gallate Inhibits Lipopolysaccharide-Induced Microglial Activation and Protects against Inflammation-Mediated Dopaminergic Neuronal Injury. J. Neurosci. Res. 2004, 78, 723-731.
112. Wei, I. H.; Wu, Y. C.; Wen, C. Y.; Shieh, J. Y. Green Tea Polyphenol (-)-Epigallocatechin Gallate Attenuates the Neuronal NADPH-d/nNOS Expression in the Nodose Ganglion of Acute Hypoxic Rats. Brain Res. 2004, 999, 73-80.
113. Lee, H.; Bae, J. H.; Lee, S. R. Protective Effect of Green Tea Polyphenol EGCG against Neuronal Damage and Brain Edema after Unilateral Cerebral Ischemia in Gerbils. J. Neurosci. Res. 2004, 77, 892-900.
114. Mandel, S.; Weinreb, O.; Amit, T.; Youdim, H. B. Cell Signaling Pathways in the Neuroprotective Actions of the Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate: Implications for Neurodegenerative Diseases. J. Neurochem. 2004, 88, 1555-1569.
115. Chang, E. J.; Mun, K. C. Effect of Epigallocatechin Gallate on Renal Function in Cyclosporine-Induced Nephrotoxicity. Transplant. Proc. 2004, 36, 2133-2134.
116. Kawai, K.; Tsuno, N. H.; Kitayama, J.; Okaji, Y.; Yazawa, K.; Asakage, M.; Sasaki, S.; Watanabe, T.; Takahashi, K.; Nagawa, H. Epigallocatechin Gallate Induces Apoptosis of Monocytes. J. Allergy Clin. Immunol. 2005, 115, 186-191.
117. Park, W. H.; Kim, S. H.; Kim, C. H. A New Matrix Metalloproteinase-9 Inhibitor 3,4-Dihydroxycinnamic Acid (Caffeic Acid) from Methanol Extract of Euonymus alatus: Isolation and Structure Determination. Toxicology 2005, 207, 383-390.
118. Shahidi, F.; Naczk, M. Food Phenolics. Sources, Chemistry, Effects, Applications. Technomic Publislung Company Inc.: Lancaster, 1995.
119. Chan, W. S.; Wen, P. C.; Chiang, H. C. Structure-Activity Relationship of Caffeic Acid Analogues on Xanthine Oxidase Inhibition. Anticancer Res. 1995, 15, 703-707.
120. Koshihara, Y.; Neichi, T.; Murota, S.; Lao, A.; Fujimoto, Y.; Tatsuno, T. Caffeic Acid Is a Selective Inhibitor for Leukotriene Biosynthesis. Biochim. Biophys. Acta 1984, 792, 92-97.
121. Michaluart, P.; Masferrer, J. L.; Carothers, A. M.; Subbaramaiah, K.; Zweifel, B. S.; Koboldt, C.; Mestre, J. R.; Grunberger, D.; Sacks, P. G.; Tanabe, T.; Dannenberg, A. J. Inhibitory Effects of Caffeic Acid Phenethyl Ester on the Activity and Expression of Cyclooxygenase-2 in Human Oral Epithelial Cells and in a Rat Model of Inflammation. Cancer Res. 1999, 59, 2347-2352.
122. Mirzoeva, O. K.; Yaqoob, P.; Knox, K. A.; Calder, P. C. Inhibition of ICE-Family Cysteine Proteases Rescues Murine Lymphocytes from Lipoxygenase Inhibitor-Induced Apoptosis. FEBS Lett. 1996, 396, 266-270.
123. Ploemen, J. H.; van Ommen, B.; de Haan, A.; Schefferlie, J. G.; Van Bladeren, P. J. In vitro and in vivo Reversible and Irreversible Inhibition of Rat Glutathione Stransferase Isoenzymes by Caffeic Acid and Its 2-S-Glutathionyl Conjugate. Food Chem. Toxicol. 1993, 31, 475-482.
124. Vieira, O.; Laranjinha, J.; Madeira, V.; Almeida, L. Cholesteryl Ester Hydroperoxide Formation in Myoglobin-Catalyzed Low Density Lipoprotein Oxidation: Concerted Antioxidant Activity of Caffeic and p-Coumaric Acids with Ascorbate. Biochem. Pharmacol. 1998, 55, 333-340.
125. Frenkel, K.; Wei, H.; Bhimani, R.; Ye, J.; Zadunaisky, J. A.; Huang, M. T.; Ferraro, T.; Conney, A. H.; Grunberger, D. Inhibition of Tumor Promoter-Mediated Processes in Mouse Skin and Bovine Lens by Caffeic Acid Phenethyl Ester. Cancer Res. 1993, 53, 1255-1261.
126. Tanaka, T.; Kojima, T.; Kawamori, T.; Wang, A.; Suzui, M.; Okamoto, K.; Mori, H. Inhibition of 4-Nitroquinoline-1-Oxide-Induced Rat Tongue Carcinogenesis by the Naturally Occurring Plant Phenolics Caffeic, Ellagic, Chlorogenic and Ferulic Acids. Carcinogenesis 1993, 14, 1321-1325.
127. Lee, H.; Kim, H. K.; Ha, T. Y. Anti-Tumor Effect of Winged Euonymus against Chemically Induced and Malignant Cell Implanted-Tumors in Mice. Korean J. Immunol. 1993, 15, 243-253.
128. Jin, U. H.; Lee, J. Y.; Kang, S. K.; Kim, J. K.; Park, W. H.; Kim, J. G.; Moon, S. K.; Kim, C. H. A Phenolic Compound, 5-Caffeoylquinic Acid (Chlorogenic Acid), Is a New Type and Strong Matrix Metalloproteinase-9 Inhibitor: Isolation and Identification from Methanol Extract of Euonymus alatus. Life Sci. 2005, 77, 2760-2769.
129. Devall, M. S. The Biological Flora of Coastal Dunes and Wetlands. 2. Ipomoea pes-caprae (L.) Roth. J. Coastal Res. 1992, 8, 442-456.
130. Teramachi, F.; Koyano, T.; Kowithayakorn, T.; Hayashi, M.; Komiyama, K.; Ishibashi, M. Collagenase Inhibitory Quinic Acid Esters from Ipomoea pes-caprae. J. Nat. Prod. 2005, 68, 794-796.
131. Drehsen, G. From Ancient Pine Bark Uses to Pycnogenol. In Antioxidant Food Supplements in Human Health; Packer, L.; Hiramatzu, M.; Yoshikawa, T., Eds.; Academic Press: New York, 1999; pp 311-322.
132. Grimm, T.; Schafer, A.; Hogger, P. Antioxidant Activity and Inhibition of Matrix Metalloproteinases by Metabolites of Maritime Pine Bark Extract (Pycnogenol). Free Radic. Biol. Med, 2004, 36, 811-822.
133. Packer, L.; Rimbach, G.; Virgili, F. Antioxidant Activity and Biologic Properties of a Procyanidin-Rich Extract from Pine (Pinus maritima) Bark, Pycnogenol. Free Radic. Biol. Med. 1999, 27,704-724.
134. Nagase, H.; Ikeda, K.; Sakai, Y. Inhibitory Effect of Magnolol and Honokiol from Magnolia Obovata on Human Fibrosarcoma HT-1080. Invasiveness in vitro. Planta Med. 2001, 67, 705-708.
135. Ikeda, K.; Sakai, Y.; Nagase, H. Inhibitory Effect of Magnolol on Tumour Metastasis in Mice. Phytother. Res. 2003, 17, 933-937.
136. Ende, C.; Gebhardt, R. Inhibition of Matrix Metalloproteinase-2 and -9 Activities by Selected Flavonoids. Planta. Med. 2004, 70, 1006-1008.
137. Parellada, J.; Suarez, G.; Guinea, M. Inhibition of Zinc Metallopeptidases by Flavonoids and Related Phenolic Compounds: Structure-Activity Relationships. J. Enzyme Inhib. 1998, 13, 347-359.
138. Fujita, M.; Nakao, Y.; Matsunaga, S.; Seiki, M.; Itoh, Y.; Yamashita, J.; van Soest, R. W.; Fusetani, N. Ageladine A: An Antiangiogenic Matrixmetalloproteinase Inhibitor from the Marine Sponge Agelas Nakamurail. J. Am. Chem. Soc. 2003, 125, 15700-15701.
139. Hodgson, J. A. Remodeling MMPIs. Biotechnology 1995, 30, 554-557.
140. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors. Chem. Rev. 1999, 99, 2735-2776.
141. Lovejoy, B.; Cleasby, A.; Hassell, A. M.; Longley, K.; Luther, M. A.;
142. Bertini, I.; Calderone, V.; Fragai, M.; Luchinat, C.; Mangani, S.; Terni, B. X-Ray Structures of Binary and Ternary Enzyme-Product-Inhibitor Complexes of Matrix Metalloproteinases. Angew. Chem. Int. Ed. Engl. 2003, 42, 2673-2676.
143. Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y. The Design, Structure, and Therapeutic Application of Matrix Metalloproteinase Inhibitors. Curr. Med. Chem. 2001, 8, 425-474.
144. Babine, R. E.; Bender, S. L. Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design. Chem. Rev. 1997, 97, 1359-1472.
145. Gall, A. L.; Ruff, M.; Kannan, R.; Cuniasse, P.; Yiotakis, A.; Dive, V.; Rio, M. C.; Basset, P.; Moras, D. Crystal Structure of Stromelysin-3 (MMP-11) Catalytic Domain Complexed with a Phosphinic Inhibitor Mimicking the Transition-State. J. Mol. Biol 2001, 307, 577-586.
146. 1' Position. J. Biol. Chem. 1998, 273, 2763-2768.
147. Vassiliou, S.; Muncha, A.; Cuniasse, P.; Georgiadis, D.; Lucet-Levannier, K.; Beau, F.; Kaman, R.; Murphy, G.; Knauper, V.; Rio, M. C.; Basset, P.; Yiotakis, A.; Dive, V. Phosphinic Pseudo-Tripeptides as Potent Inhibitors of Matrix-Metalloproteinases: A Structure-Activity Study. J. Med. Chem. 1999, 42, 2610-2620.
148. Kontogiorgis, C. A.; Papaioannou, P.; Hadjipavlou-Litina, D. J. Matrix Metalloproteinase Inhibitors: A Review on Pharmacophore Mapping and (Q)Sars Results. Curr. Med. Chem. 2005, 12, 339-355.
149. Matter, H.; Schudok, M. Recent Advances in the Design of Matrix Metalloproteinase Inhibitors. Curr. Opin. Drug Disc. Devel 2004, 7, 513-535
150. Cuniasse, P.; Level, L.; Makaritis, A.; Beau, F.; Georgiadis, D.; Matziari, M.; Yiotakis, A.; Dive, V. Future Challenges Facing the Development of Specific Active-Site-Directed Synthetic Inhibitors of MMPs. Biochimie 2005, 87, 393402.
151. Nishino, N.; Powers, J. C. Peptide Hydroxamic Acids as Inhibitors of Thermolysin. Biochemistry 1978, 17, 2846-2850.
152. Moore, W. M.; Spilburg, C. A. Peptide Hydroxamic Acids Inhibit Skin Collagenase. Biochem. Biophys, Res. Commun. 1986, 136, 390-399.
153. Moore, W. M.; Spilburg, C. A. Purification of Human Collagenase with a Hydroxamic Acid Affinity Column. Biochemistry 1986, 25 5189-5195.
154. Robinson, R. P.; Laird, E. R.; Blake, J. F.; Bordner, J.; Donahue, K. M.; Lopresti-Morrow, L. L.; Mitchell, P. G.; Reese, M. R.; Reeve, L. M.; Stam, E. J.; Yocum, S. A. Structure-Based Design and Synthesis of a Potent Matrix Metalloproteinase-13 Inhibitor Based on a Pyrrolidinone Scaffold. J. Med. Chem. 2000, 43, 2293-2296.
155. Robinson, R. P.; Laird, E. R.; Donahue, K. M.; Lopresti-Morrow, L. L.; Mitchell, P. G.; Reese, M. R.; Reeve, L. M.; Rouch, A. I.; Stam, E. J.; Yocum, S. A. Design and Synthesis of 2- Oxoimidazolidine-4-Carboxylic Acid Hydroxyamide as Potent Matrix Metalloproteinase-13 Inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1211-1213.
156. Aranapakam, V.; Davis, J. M.; Grosu, G. T.; Baker, J. L.; Ellingboe, J.; Zask, A.; Levin, J. I.; Sandanayaka, V. P.; Du, M.; Skotnicki, J. S.; DiJoseph, J. F.; Sung, A.; Zhao, W.; McDevitt, J.; Xu, Z. B. Synthesis and Structure-Activity Relationship of N- Substituted 4-Arylsulfonylpiperidine-4-Hydroxamic Acids as Novel, Orally Active Matrix Metalloproteinase Inhibitors for the Treatment of Osteoarthritis. J. Med. Chem. 2003, 46, 2376-2396.
157. Aranapakam, V.; Grosu, G. T.; Davis, J. M.; Hu, B.; Ellingboe, J.; Baker, J. L.; Skotnicki, J. S.; Zask, A.; DiJoseph, J. F.; Sung, A.; Sharr, M. A.; Killar, L. M.; Walter, T.; Jin, G.; Cowling, R. Synthesis and Structure-Activity Relationship of α- Sulfonylhydroxamic Acids as Novel, Orally Active Matrix Metalloproteinase Inhibitors for the Treatment of Osteoarthritis. J. Med. Chem. 2003, 46, 2361-2375.
158. Aranapakam, M. V.; Davis, J. M.; Grosu, G. T.; Baker, J.; Ellingboe, J.; Zask, A.; Levin, J. I.; Ellingboe, J.; Skotnicki, J. S.; DiJoseph, J. F.; Sung, A.; Jin, G.; Xu, W.; McCarthy, D. J.; Barone, D. Synthesis and Structure-Activity Relationships of 4- Alkynyloxyphenyl Sulfonyl, Sulfinyl, and Sulfonyl Alkyl Hydroxamates as Tumour Necrosis Factor-α Converting Enzyme and Matrix Metalloproteinase Inhibitors. J. Med. Chem. 2004, 47, 6255-6269.
159. Noe, M. C.; Snow, S. L.; Wolf-Gouveia, L. A.; Mitchell, P. G.; Lopresti-Morrow, L.; Reeves, L. M.; Yocum, S. A.; Liras, J. L.; Vaughn, M. 3-Hydroxy-4-Arysulfonyltetrahydrohydropyranyl-3- Hydroxamic Acids Are Novel Inhibitors of MMP-13 and Aggrecanase. Bioorg, Med. Chem. Lett. 2004, 14, 4727-4730.
160. Salvino, J. M.; Mathew, R.; Kiesow, T.; Narensingh, R.; Mason, H. J.; Dodd, A.; Groneberg, R.; Burns, C. J.; McGeehan, G.; Kline, J.; Orton, E.; Tang, S. Y.; Morrisette, M.; Labaudininiere, R. Solid-Phase Synthesis of an Arylsulfone Hydroxamate Library. Bioorg. Med. Chem. Lett. 2000, 10, 1637-1640.
161. Sandi, M.; Candiani, G.; Pecker, F.; Malpezzi, L.; Zanda, M. Novel Highly Potent, Structurally Simple γ-Trifluoromethyl γ-Sulfone Hydroxamate Inhibitor of Stromelysin-1 (MMP-3). Tetrahetron Lett. 2005, 46, 2393-1936.
162. Scozzafava, A.; Supuran, C. T. Protease Inhibitors: Synthesis of Potent Bacterial Collagenase and Matrix Metalloproteinase Inhibitors Incorporating N-4-Nitrobenzylsulfonylglycine Hydroxamate Moieties. J. Med. Chem. 2000, 43, 1858-1865.
163. O'Brien, P. M.; Ortwine, D. F.; Pavlovsky, A. G.; Picard, J. A.; Sliskovic, D. R.; Roth, B. D.; Dyer, R. D.; Johnson, L. L.; Man, C. F.; Hallk, H. Structure-Activity Relationship and Pharmacokinetic Analysis for a Series of Potent, Systemically Available Biphenylsulfonamide Matrix Metalloproteinase Inhibitors. J. Med. Chem. 2000, 43, 156-166
164. Ilies, M.; Banciu, M. D.; Scozzafava, A.; Ilies, M. A.; Caproiu, T.; Supuran, C. T. Protease Inhibitors: Synthesis of Bacterial Collagenase and Matrix Metalloproteinase Inhibitors Incorporating Arylsulfonylureido and 5-Dibenzo-Subernyl/Suberyl Moieties. Bioorg. Med. Chem. 2003, 11, 2227-2239.
165. Rossello, A.; Nuti, E.; Carlli, P.; Orlandini, E.; Macchia, M.; Nencetti, S.; Zandomeneghi, M.; Balzano, F.; Barretta, G. U.; Albini, A.; Benelli, R.; Cercignani, G.; Murphy, G.; Balsamo, A. N-i-Propoxy-N-Biphenylsulfonylaminobutylhydroxamic Acids as Potent and Selective Inhibitors of MMP-2 and MT1-MMP. Bioorg. Med. Chem. Lett. 2005, 15, 1321-1326.
166. Rossello, A.; Nuti, E.; Orlandini, E.; Carlli, P.; Rapposelli, S.; Macchia, M.; Minutolo, F.; Carbonaro, L.; Albini, A.; Benelli, R.; Cercignani, G.; Murphy, G.; Balsamo, A. New N-Arylsulfonyl-N-Alkoxyaminoacetohydroxamic Acids as Selective Inhibitors of Gelatinase A (MMP-2). Bioorg. Med. Chem. 2004, 12, 2441-2450.
167. Clare, B. W.; Scozzafava, A.; Supuran, C. T. Protease Inhibitors: Synthesis of a Series of Bacterial Collagenase Inhibitors of the Sulfonyl Amino Acyl Hydroxamate Type. J. Med. Chem. 2001, 44, 2253-2258.
168. 2′ Pockets. J. Med. Chem. 2001, 44, 3066-3073.
169. Reiter, L. A.; Robinson, R. P.; McClure, K. F.; Jones, C. S.; Reese, M. R.; Mitchell, P. R.; Otterness, I. G.; Bliven, M. L.; Liras, J.; Cortina, S. R.; Donahue, K. M.; Eskra, J. D.; Griffiths, R. J.; Lame, M. E.; Lopez-Anaya, A.; Martinelli, G. J.; McGahee, S. M.; Yocum, S. A.; Lopresti-Morrow, L. L.; Tobiassen, L. M.; Vaughn-Bowser, M. L. Pyran-Containing Sulfonamide Hydroxamic Acids; Potent MMP Inhibitors That Spare MMP-1. Bioorg, Med. Chem. Lett. 2004, 14, 3389-3395.
170. Almstead, N. G.; Bradley, R. S.; Pikul, S.; De, B.; Natchus, M. G.; Taiwo, Y. O.; Gu, F.; Williams, L. E.; Hynd, B. A.; Janusz, M. J.; Dunaway, C. M.; Mieling, G. E. Design, Synthesis, and Biological Evaluation of Potent Thiazine- and Thiazepine-Based Matrix Metalloproteinase Inhibitors. J. Med. Chem. 1999, 42, 4547-4562.
171. 2′ Substituents. Bioorg. Med. Chem. Lett. 2001, 11, 1009-1013.
172. Zask, A.; Kaplan, J.; Du, X. M.; MacEwan, G.; Sandanayaka, V.; Eudy, N.; Levin, J.; Jin, G.; Xu, J.; Cummons, T.; Barone, D.; Ayral-Kalostian, S.; Skotnicki, J. Synthesis and SAR of Diazepine and Thiazepine TACE and MMP Inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 1641-1645.
173. Levin, J. I.; Nelson, F. C.; Santos, E. D.; Du, M. T.; MacEwan, G.; Chen, J. M.; Ayral-Kalostian, S.; Xu, J.; Jin, G.; Cummons, T.; Barone, D. Benzodiazepine Inhibitors of the MMPs and TACE. Part 2. Bioorg. Med. Chem. Lett. 2004, 14, 4147-4151.
174. Nelson, F. C.; Santos, E. D.; Levin, J. I.; Chen, J. M.; Skotnicki, J. S.; DiJoseph, J. F.; Sharr, M. A.; Sung, A.; Killar, L. M.; Cowling, R.; Jin, G.; Roth, C. E.; Albright, J. D. Benzodiazepine Inhibitors of the MMPs and TACE. Bioorg. Med. Chem. Lett. 2002, 12, 2867-2870.
175. Cheng, M.; De, B.; Almstead, N. G.; Pikul, S.; Dowty, M. E.; Dietsch, C. R.; Dunaway, C. M.; Gu, F.; Hsieh, L. C.; Janusz, M. J.; Taiwo, Y. O.; Natchus, M. G. Design, Synthesis, and Biological Evaluation of Matrix Metalloproteinase Inhibitors Derived from a Modified Proline Scaffold. J. Med. Chem. 1999, 42, 5426-5436
176. Gupta, S. P.; Kumar, D.; Kumaran, S. A Quantitative Structure Activity Relationship Study of Hydroxamate Matrix Metalloproteinase Inhibitors Derived from Functionalized 4-Aminoprolines. Bioorg. Med. Chem. 2003, 11, 1975-1981.
177. Natchus, M. G.; Bookland, R. G.; De, B.; Almstead, N. G.; Pikul, S.; Janus, M. J.; Heitmeyer, S. A.; Hookfin, E. B.; Hsieh, L. C.; Dowty, M. E.; Dietsch, C. R.; Patel, V. S.; Garver, S. M.; Gu, F.; Pokross, M. E.; Mieling, G. E.; Backer, T. R.; Foltz, D. J. Development of New Hydroxamate Matrix Metalloproteinase Inhibitors Derived from Functionalized 4-Aminoprolines. J. Med. Chem. 2000, 43, 4948-4963.
178. Cheng, M.; De, B.; Pikul, S.; Almstead, N. C.; Natchus, M. G.; Anastasio, M. V.; McPhail, S. J.; Snider, C. E.; Taiwo, Y. O.; Chen, L.; Dunaway, C. M.; Gu, F.; Dowty, M. E.; Mieling, G. E.; Janusz, M. J.; Wang-Weigland, S. Design and Synthesis of Piperazine-Based Matrix Metalloproteinase Inhibitors. J. Med. Chem. 2000, 43, 369-380.
179. Letavic, M. A.; Axt, M. Z.; Barberia, J. T.; Carty, T. J.; Danley, D. E.; Geoghegan, K. F.; Halim, N. S.; Hoth, L. R.; Kamath, A. V.; Laird, E. R.; Lopresti-Morrow, L. L.; McClure, K. F.; Mitchell, P. G.; Natarajan, V.; Noe, M. C.; Pandit, J.; Reeves, L.; Schulte, G. K.; Snow, S. L.; Sweeney, F. J.; Tan, D. H.; Yu, C. H. Synthesis and Biological Activity of Selective Pipecolic Acid-Based TNF-α- Converting Enzyme (TACE) Inhibitors. Bioorg. Med. Chem. 2002, 12, 1387-1390.
180. Noe, M. C.; Natarajan, V.; Snow, S. L.; Mitchell, P. G.; Lopresti-Morrow, L.; Reeves, L. M.; Yocum, S. A.; Carty, T. J.; Arberia, J. A.; Sweeney, F. J.; Liras, J. L.; Vaughn, M.; Hardink, J. R.; Hawkins, J. M.; Tokar, C. Discovery of 3,3-Dimethyl-5-Hydroxypipecolic Hydroxamate-Based Inhibitors of Aggrecanase and MMP-13. Bioorg. Med. Chem. Lett. 2005, 15, 2808-2811.
181. Noe, M. C.; Natarajan, V.; Snow, S. L.; Wolf-Gouveia, L. A.; Mitchell, P. G.; Lopresti-Morrow, L.; Reeves, L. M.; Yocum, S. A.; Otterness, I.; Bliven, M. A.; Carty, T. J.; Barberia, J. T.; Sweeney, F. J.; Liras, J. L.; Vaughn, M. Discovery of 3-OH-3-Methylpipecolic Hydroxamates: Potent Orally Active Inhibitors of Aggrecanase and MMP-13. Bioorg. Med. Chem. Lett. 2005, 15, 3385-3388.
182. Moriyama, H.; Tsukida, T.; Inoue, Y.; Kondo, H.; Yoshino, K.; Nishimura, S. I. Structure-Activity Relationships of Azasugar-Based MMP/ADAM Inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 2737-2740.
183. Ma, D.; Wu, W.; Yang, G.; Li, J.; Li, J.; Ye, Q. Tetrahydroisoquinoline Based Sulfonamide Hydroxamates as Potent Matrix Metalloproteinase Inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 47-50.
184. Cherney, R. J.; Mo, R.; Meyer, D. T.; Hardman, K. D.; Liu, R. Q.; Covington, M. B.; Qian, M.; Wasserman, Z. R.; Christ, D. D.; Trzaskos, J. M.; Newton, R. C.; Decicco, C. P. Sultam Hydroxamates as Novel Matrix Metalloproteinase Inhibitors. J. Med. Chem. 2004, 47, 2, 981-2983.
185. Sawa, M.; Kiyoi, T.; Kurokawa, K.; Kumihara, H.; Yamamoto, M.; Miyasaka, T.; Ito, Y.; Hirayama, R.; Inoue, T.; Kirii, Y.; Nishiwaki, E.; Ohmoto, H.; Maeda, Y.; Ishibushi, E.; Inoue, Y.; Yoshino, K.; Kondo, H. New Type of Metalloproteinase Inhibitor: Design and Synthesis of New Phosphonamide-Based Hydroxamic Acids. J. Med. Chem. 2002, 45, 919-929.
186. Sawa, M.; Tsukamoto, T.; Kiyoi, T.; Kurokawa, K.; Nakajima, F.; Nakada, Y.; Yokada, K.; Inoue, Y.; Yoshino, K. New Strategy for Antedrug Application: Development of Metalloproteinase Inhibitors as Antipsoriatic Drugs. J. Med. Chem. 2002, 45, 930-936.
187. Sorensen, M. D.; Blahr, L. K. A.; Christensen, M. K.; Hoyer, T.; Latini, S.; hajarnaa, P. J. V.; Bjorkling, F. Cyclic Phosphinamides and Phosphonamides, Novel Series of Potent Matrix Metalloproteinase Inhibitors with Antitumour Activity. Bioorg. Med. Chem. 2003, 11, 5461-5484.
188. 1′ Groups. Bioorg. Med. Chem. Lett. 2001, 11, 2189-2192.
189. Levin, J. I.; Chen, J. M.; Du, M. T.; Nelson, F. C.; Wehr, T.; DiJoseph, J. F.; Killar, L. M.; Skala, S.; Sung, A.; Sharr, M. A.; Roth, C. E.; Jin, G.; Cowling, R.; Di, L.; Sherman, M.; Xu, Z. B.; March, C. J.; Mohler, K. M.; Black, R. A.; Skotnicki, J. S. The Discovery of Anthranilic Acid-Based MMP Inhibitors. Part 3: Incorporation of Basic Amines. Bioorg. Med. Chem. Lett. 2001, 11, 2975-2978.
190. Levin, J. I.; Do, M. T.; DiJoseph, J. F.; Killar, L. M.; Sung, A.; Walter, T.; Sharr, M. A.; Roth, C. E.; Moy, F. J.; Powers, R.; Jin, G.; Cowling, R.; Skotnicki, J. S. The Discovery of Anthranilic Acid-Based MMP Inhibitors, Part 1: SAR of the 3-Position. Bioorg. Med. Chem. Lett. 2001, 11, 235-238.
191. Levin, J. I.; Gu, Y.; Nelson, F. C.; Zask, A.; DiJoseph, J. F.; Sharr, M. A.; Sung, A.; Jin, G.; Cowling, R.; Chanda, P.; Cosmi, S.; Hsiao, C. L.; Edris, W.; Wilhelm, J.; Killar, L. M.; Skotnicki, J. S. Heteroaryl and Cycloalkyl Sulfonamide Hydroxamic Acid Inhibitors of Matrix Metalloproteinases. Bioorg, Med. Chem. Lett. 2001, 11, 239-242.
192. Peterson, J. T. Matrix Metalloproteinase Inhibitor Development and the Remodeling of Drug Discovery. Heart Failure Rev. 2004, 9, 63-79.
193. Delbecq, F.; Cordonnier, G.; Pommery, N.; Barbry, D.; Henichart, J. P. New Hetereoarylbezenesulphonamides as Matrix Metalloproteinase Inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 1119-1121.
194. Natchus, M. G.; Bookland, R. G.; Laufersweiler, M. J.; Pikul, S.; Almstead, N. G.; de, B.; Janus, M. J.; Hsieh, L. C.; Go, F.; Porkross, M. E.; Patel, V. S.; Garver, S. M.; Peng, S. X.; Branch, T. M.; King, S. L.; Baker, T. R.; Foltz, D. J.; Mieling, G. E. Development of New Carboxylic Acid-Based MMP Inhibitors Derived from Functionalized Propargylglycines. J. Med. Chem. 2001, 44, 1060-1070.
195. Tullis, J. S.; Laufersweiler, M. J.; VanRens, J. C.; Natchus, M. G.; Bookland, R. G.; Almstead, N. G.; Pikul, S.; De, B.; Hsieh, L. C.; Janusz, M. J.; Branch, T. M.; Peng, S. X.; Jin, Y. Y.; Hudlicky, T.; Oppong, K. The Development of New Carboxylic Acid-Based MMP Inhibitors Derived from a Cyclohexylglycine Scaffold. Bioorg. Med. Chem. Lett. 2001, 11, 1975-1979.
196. Pikul, S.; Ohler, N. E.; Ciszewski, G.; Laufersweiler, M. C.; Almstead, N. G.; De, B.; Natchus, M. G.; Hsieb, L. C.; Janus, M. J.; Peng, S. X.; Branch, T. M.; King, S. L.; Taiwo, Y. O.; Mieling, G. E. Potent and Selective Carboxylic Acid-Based Inhibitors of Matrix Metalloproteinases. J. Med. Chem. 2001, 44, 2499-2502.
197. Matter, H.; Schudok, M.; Schwab, W.; Thorwart, W.; Barbier, D.; Billen, G.; Haase, B.; Neises, B.; Weithmann, K. U.; Wollmann, T. Tetrahydroisoquinoline-3-Carboxylate Based Matrix-Metalloproteinase Inhibitors; Design, Synthesis, and Structure-Activity Relationship. Bioorg. Med. Chem. 2002, 10, 3529-3544.
198. Dive, V.; Lucet-Levannier, K.; Georgiadis, D.; Cotton, J.; Vassiliou, S.; Cuniasse, P.; Yiotakis, A. Phosphinic Peptide Inhibitors as Tools in the Study of the Function of Zinc Metalloproteinases. Biochem. Soc. Trans. 2000, 28, 455-60.
199. Makaritis, A.; Georgiadis, D.; Dive, V.; Yiotakis, A. Diastereoselective Solution and Multipin-Based Combinatorial Array Synthesis of a Novel Class of Potent Phosphinic Metalloprotease Inhibitors. Chemistry-A Eur. J. 2003, 9, 2079-2094.
200. Dive, V.; Andarawewa, K. L.; Boulay, A.; Matziari, M.; Beau, F.; Guerin, E.; Rousseau, B.; Yiotakis, A.; Rio, M. C. Dosing and Scheduling Influence the Antitumor Efficacy of a Phosphinic Peptide Inhibitor of Matrix Metalloproteinases. International J. Cancer 2005, 113, 775-781.
201. 1'-Diversified Phosphinic Peptides Leads to the Development of Highly Selective Inhibitors of MMP-11. J. Med. Chem. 2004, 47, 325-336.
202. Breuer, E.; Salomon, C. J.; Katz, Y.; Chen, W.; Lu, S.; Roschenthaler, G. V.; Hadar, R.; Reich, R. Carbamoylphosphonates, a New Class of in vivo Active Matrix Metalloproteinase Inbibitors. 1. Alkyl- and Cycloalkylcabamoylphosphonic Acids. J. Med. Chem. 2004, 47, 2826-2832.
203. Pergament, I.; Reich, R.; Srebnik, M. Novel Matrix-Proteinase (MMP-2) Phosphonoboronate Inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 1215-1218.
204. Bianchini, G.; Aschi, M.; Cavicchio, G.; Crucianelli, M.; Preziuso, S.; Gallina, C.; Nastari, A.; Gavuzzo, E.; Mazza, F. Design, Modelling, Synthesis and Biological Evaluation of Peptidomimetic Phosphinates as Inhibitors of Matrix Metalloproteinases MMP-2 and MMP-8. Bioorg. Med. Chem. 2005, 13, 4740-4749.
205. White, C. M. Pharmacologic, Pharmacokinetic, and Therapeutic Differences among ACE Inhibitors. Pharmacotherapy 1998, 18, 588-599.
206. Gordon, A. M. Coordination Chemistry of Macrocyclic Compounds. Plenum Press: New York, 1979.
207. Schwartz, M. A.; Van Wart, H. E. Mercaptosulfide Metalloproteinase Inhibitors. U.S. Patent 5455262, Oct. 3, 1995.
208. Hurst, D. R.; Schwartz, M. A.; Jin, Y.; Ghaffari, M. A.; Kozarekar, P.; Cao, J.; Sang, Q. X. A. Inhibition of Enzyme Activity and Cell-Mediated Substrate Cleavage of Membrane Type 1-Matrix Metalloproteinase by Newly Developed Mercaptosulfide Inhibitors. Biochem. J. 2005, 392, 527-536.
209. Jia, M.-C.; Schwartz, M. A.; Sang, Q. A. Suppression of Human Microvascular Endothelial Cell Invasion and Morphogenesis with Synthetic Matrixin Inhibitors. Targeting Angiogenesis with MMP Inhibitors. Adv. Exp. Med. Biol. 2000, 476, 181-194.
210. Hurst, D. R.; Schwartz, M. A.; Ghaffari, M. A.; Jin, Y.; Tschesche, H.; Fields, G. B.; Sang, Q. X. Catalytic- and Ecto-Domains of Membrane Type 1-Matrix Metalloproteinase Have Similar Inhibition Profiles but Distinct Endopeptidase Activities. Biochem. J. 2004, 377, 775-779.
211. 1' Pocket of the Endometase/ Matrilysin-2 Active Site Revealed by Enzyme Inhibition Kinetic Studies, Protein Sequence Analyses, and Homology Modeling. J. Biol. Chem. 2003, 278, 51646-51653.
212. Sang, Q. X.; Jia, M. C.; Schwartz, M. A.; Jaye, M. C.; Kleinman, H. K.; Ghaffari, M. A.; Luo, Y. L. New Thiol and Sulfodiimine Metalloproteinase Inhibitors and Their Effect on Human Microvascular Endothelial Coll Growth. Biochem. Biophys. Res. Commun. 2000, 274, 780-786.
213. Sang, Q. X. A.; Schwartz, M. A.; Li, H.; Chung, L. W. K.; and Zhau, H. E. Targeting Matrix Metalloproteinases in Human Prostate Cancer. Ann. NY Acad. Sci. 1999, 878, 538-540.
214. Jin, Y.; Ghaffari, M. A.; Schwartz, M. A. A Practical Synthesis of Differentially-Protected Cis- 1,2-Cyclopentanedithiols and Cis-3,4-Pyrrolidinedithiols. Tetrahedron Lett. 2002, 43, 7319-7321.
215. Cook, G. R.; Manivannan, E.; Underdahl, T.; Lukacova, V.; Zhang, Y.; Balaz, S. Synthesis and Evaluation of Novel Oxazoline MMP Inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 4935-4939.
216. Puerta, D. T.; Lewis, J. A.; Coen, S. M. New Beginnings for Matrix Metalloproteinase Inhibitors: Identification of High-Affinity Zinc-Binding Groups. J. Am. Chem. Soc. 2004, 126, 8388-8389.
217. Grams, F.; Mermann, G. Preparation of Pyrimidin-2,4,6-Triones as Metalloprotease Inhibitors. PCT Int. Appl. WO9858915, 1998.
218. Brandstetter, H.; Grams, F.; Glitz, D.; Lang, A.; Huber, R.; Bode, W.; Krell, H. W.; Engh, R. A. The 1.8 Å Crystal Structure of a Matrix Metalloproteinase 8-Barbiturate Inhibitor Complex Reveals a Previously Unobserved Mechanism for Collagenase Substrate Recognition. J. Biol Chem. 2001, 276, 17405-17412.
219. Dunten, P.; Kammlott, U.; Crowther, R.; Levin, W.; Foley, L. H.; Wang, P.; Palermo, R. X-Ray Structure of a Novel Matrix Metalloproteinase Inhibitor Complexed to Stromelysin. Protein Sci. 2001, 10, 923-926.
220. Foley, L. H.; Palermo, R.; Dunten, P.; Wang, P. Novel 5,5-Disubstituted Pyrimidine-2,4,6-Triones as Selective MMP Inhibitors. Bioorg, Med. Chem. Lett. 2001, 11, 969-972.
221. Blagg, J. A.; Noe, M. C.; Wolf-Gouveia, L. A.; Reiter, L. A.; Laird, E. R.; Chang, S. P. P.; Danley, D. E.; Downs, J. T.; Elliott, A. I.; Eskra, J. D.; Griffiths, R. J.; Hardink, J. R.; Haugeto, A. I.; Jones, C. S.; Liras, J. L.; Lopresti-Morrow, L. L.; Mitchell, P. G.; Pandit, J.; Robinson, R. P.; Subramanyam, C.; Vaughn, B. M. L.; Tocum, S. A. Potent Pyrimidinetrione-Based Inhibitors of MMP-13 with Enhanced Selectivity over MMP-14. Bioorg. Med. Chem. Lett. 2005, 15, 1807-1810.
222. Kim, S. H.; Pudzianowski, A. T.; Leavitt, K. J.; Barbosa, J.; McDonnell, P. A.; Metzler, W. L; Rankin, B. M.; Liu, R.; Vaccaro, W.; Pitts, W. Structure-Based Design of Potent and Selective Inhibitors of Collagenase-3 (MMP-13). Bioorg. Med. Chem. Lett. 2005, 15, 1101-1106.
223. Auge, F.; Hornebeck, W.; Decarme, M.; Laronze, J. Y. Improved Gelatinase A Selectivity by Novel Zinc Binding Groups Containing Galardin Derivatives. Bioorg. Med. Chem. Lett. 2003, 13, 1783-1786.
224. Wang, X.; Choe, Y.; Craik, C. S.; Ellman, J. A. Design and Synthesis of Novel Inhibitors of Gelatinase B. Bioorg. Med. Chem. Lett. 2002, 12, 2201-2204.
225. Brown, S.; Bermardo, M. M.; Li, Z. H.; Kotra, L. P.; Tanaka, Y.; Friman, R.; Mobashery, S. Potent and Selective Mechanism-Based Inhibition of Gelatinases. J. Am. Chem. Soc. 2000, 122, 6799-6800.
226. Ikejiri, M.; Bermardo, M. M.; Meroueh, S. O.; Brown, S.; Chang, M.; Fridman, R.; Mobashery, S. Design, Synthesis, and Evaluation of a Mechanism-Based Inhibitor for Gelatinase A. J. Org. Chem. 2005, 70, 5709-5712.
227. Lim, I. T.; Brown, S.; Mobashery, S. A Convenient Synthesis of a Selective Gelatinase Inhibitor as an Antimetastatic Agent. J. Org. Chem. 2004, 69, 3572-3573.
228. Chen, J. M.; Nelson, F. C.; Levin, J. I.; Mobilio, D.; Moy, F. J.; Nilakantan, R.; Zask, A.; Powers, R. Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design. J. Am. Chem. Soc. 2000, 122, 9648-9654.
229. Morales, R.; Perrier, S.; Florent, J. M.; Beltra, J.; Dufour, S.; Mendez, I. D.; Manceau, P.; Tertre, A.; Moreau, F.; Compere, D.; Dublanchet, A. C.; Gara, M. O. Crystal Structure of Novel Non-Peptidic, Non-Zinc Chelating Inhibitors Bound to MMP-12. J. Mol. Biol. 2004, 341, 1063-1076.
230. Engel, C. K.; Pirard, B.; Schimanski, S.; Kirsch, R.; Habermann, J.; Klingler, O.; Schlotte, V.; Weithmann, K. U.; Wendt, K. U. Structural Basis for the Highly Selective Inhibition of MMP-13. Chem. Biol. 2005, 12, 181-189
231. Bunker, A. M.; Picard, J. A. Preparation of Quinazolinyl Amides and Esters as Matrix Metalloproteinase Inhibitors. U.S. Patent 2004142950, 2004.
232. Bunker, A. M.; Picard, J. A.; Lodaya, R. M.; Waldo, M. L.; Marlett, M. E. Preparation of Pyrido[3,4-D]Pyrimidine Derivatives as Matrix Metalloproteinase-13 Inhibitors. PCT Int. Appl. WO2005016926, 2005.
233. Otmar, K.; Reinhard, K.; Joerg, H.; Klaus-Ulrich, W. C. E.; Bernard, P. Preparation of Pyrimidinedicarboxamides as Selective MMP-13 Inhibitors. Ger. Offen. DE10300017, 2004.
234. Koivunen, E.; Arap, W.; Valtanen, H:; Rainisalo, A.; Medina, O. P.; Heikkila, P.; Kantor, C.; Gahmberg, C. G.; Salo, T.; Konttinen, Y. T.; Sorsa, T.; Ruoslahti, E.; Pasqualini, R. Tumor Targeting with a Selective Gelatinase Inhibitor. Nat. Biotechno 1999, 17, 768-774.
235. Milner, J. M.; Cawston, T,. E. Matrix Metalloproteinase Knockout Studies and the Potential Use of Matrix Metalloproteinase Inhibitors in the Rheumatic Diseases. Curr. Drug. Targets Inflamm. Allergy 2005, 4, 363-375.
236. Burrage, P. S.; Mix, K. S.; Brinckerhoff, C. E. Matrix Metalloproteinases: Role in Arthritis. Front Biosci. 2006, 11, 529-543.